Binding of the sea anemone polypeptide BDS II to the voltage-gated sodium channel

L. E. Llewellyn, R. S. Norton

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

BDS II, a 43 - residue polypeptide from the sea anemone Anemonia sulcata, is reported to have both antihypertensive and antiviral activity. This polypeptide possesses a number of sequence and structural similarities to a class of cardiotonic proteins which bind to receptor site 3 of the voltage-gated sodium channel. In contrast to these cardiostimulant proteins, which produce positive inotropic effects at concentrations of 2-15nM, BDS II produced a weak negative inotropic effect upon isolated guinea-pig atria, with doses of 90 and 180nM depressing contractile strength by 15 and 28%, respectively. BDS II also competed with a 125-iodine labelled derivative of AP-A (a representative of the cardiostimulant proteins) bound to sodium channels in rat brain synaptosomes. The IC50 for BDS II versus AP-A was 5.2μM. BDS II may therefore be considered an antagonist for receptor site 3 of the voltage-gated sodium channel. Structural differences between BDS II and the agonist AP-A which may give rise to their different effects on the sodium channel are considered.

Original languageEnglish
Pages (from-to)937-946
Number of pages10
JournalBiochemistry International
Volume24
Issue number5
Publication statusPublished - 1991
Externally publishedYes

Cite this

@article{f48246de6d78423da585a59799a88751,
title = "Binding of the sea anemone polypeptide BDS II to the voltage-gated sodium channel",
abstract = "BDS II, a 43 - residue polypeptide from the sea anemone Anemonia sulcata, is reported to have both antihypertensive and antiviral activity. This polypeptide possesses a number of sequence and structural similarities to a class of cardiotonic proteins which bind to receptor site 3 of the voltage-gated sodium channel. In contrast to these cardiostimulant proteins, which produce positive inotropic effects at concentrations of 2-15nM, BDS II produced a weak negative inotropic effect upon isolated guinea-pig atria, with doses of 90 and 180nM depressing contractile strength by 15 and 28{\%}, respectively. BDS II also competed with a 125-iodine labelled derivative of AP-A (a representative of the cardiostimulant proteins) bound to sodium channels in rat brain synaptosomes. The IC50 for BDS II versus AP-A was 5.2μM. BDS II may therefore be considered an antagonist for receptor site 3 of the voltage-gated sodium channel. Structural differences between BDS II and the agonist AP-A which may give rise to their different effects on the sodium channel are considered.",
author = "Llewellyn, {L. E.} and Norton, {R. S.}",
year = "1991",
language = "English",
volume = "24",
pages = "937--946",
journal = "Biochemistry International",
issn = "0158-5231",
publisher = "Wiley-Blackwell",
number = "5",

}

Binding of the sea anemone polypeptide BDS II to the voltage-gated sodium channel. / Llewellyn, L. E.; Norton, R. S.

In: Biochemistry International, Vol. 24, No. 5, 1991, p. 937-946.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Binding of the sea anemone polypeptide BDS II to the voltage-gated sodium channel

AU - Llewellyn, L. E.

AU - Norton, R. S.

PY - 1991

Y1 - 1991

N2 - BDS II, a 43 - residue polypeptide from the sea anemone Anemonia sulcata, is reported to have both antihypertensive and antiviral activity. This polypeptide possesses a number of sequence and structural similarities to a class of cardiotonic proteins which bind to receptor site 3 of the voltage-gated sodium channel. In contrast to these cardiostimulant proteins, which produce positive inotropic effects at concentrations of 2-15nM, BDS II produced a weak negative inotropic effect upon isolated guinea-pig atria, with doses of 90 and 180nM depressing contractile strength by 15 and 28%, respectively. BDS II also competed with a 125-iodine labelled derivative of AP-A (a representative of the cardiostimulant proteins) bound to sodium channels in rat brain synaptosomes. The IC50 for BDS II versus AP-A was 5.2μM. BDS II may therefore be considered an antagonist for receptor site 3 of the voltage-gated sodium channel. Structural differences between BDS II and the agonist AP-A which may give rise to their different effects on the sodium channel are considered.

AB - BDS II, a 43 - residue polypeptide from the sea anemone Anemonia sulcata, is reported to have both antihypertensive and antiviral activity. This polypeptide possesses a number of sequence and structural similarities to a class of cardiotonic proteins which bind to receptor site 3 of the voltage-gated sodium channel. In contrast to these cardiostimulant proteins, which produce positive inotropic effects at concentrations of 2-15nM, BDS II produced a weak negative inotropic effect upon isolated guinea-pig atria, with doses of 90 and 180nM depressing contractile strength by 15 and 28%, respectively. BDS II also competed with a 125-iodine labelled derivative of AP-A (a representative of the cardiostimulant proteins) bound to sodium channels in rat brain synaptosomes. The IC50 for BDS II versus AP-A was 5.2μM. BDS II may therefore be considered an antagonist for receptor site 3 of the voltage-gated sodium channel. Structural differences between BDS II and the agonist AP-A which may give rise to their different effects on the sodium channel are considered.

UR - http://www.scopus.com/inward/record.url?scp=0026008949&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 937

EP - 946

JO - Biochemistry International

JF - Biochemistry International

SN - 0158-5231

IS - 5

ER -